Publications by authors named "Adrien Daniel"
Article Synopsis
- Late relapse (LR) after a special blood stem cell treatment for leukemia happens in about 4.5% of patients and is studied to find out how well they do after this happens.
- A study looked at 7,582 patients who had the treatment, and 319 of them had late relapses, mostly after about 38 months.
- The chances of living longer after a late relapse were about 19.9 months, with many patients getting better after a second treatment.
Background: Autoimmune conditions in B-cell lymphomas are frequent. Steroids are standard of care, but many patients require other immunosuppressive agents. Ibrutinib is a Bruton Tyrosine Kinase inhibitor that is approved for B-cell indolent lymphoma treatment.
View Article and Find Full Text PDFArticle Synopsis
- Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is an aggressive, rare form of T-cell lymphoma mainly found in Asia, with a clinical study conducted on 71 European patients showing a median age of 67 years.
- Most patients had gastrointestinal symptoms requiring emergency surgery, with around 40% diagnosed at stage IV, and tumors were classified into typical and atypical morphologies sharing similar immunophenotypic profiles.
- The study highlighted significant genetic alterations, including mutations in genes like MYC, STAT5B, and TP53, which are associated with poor survival outcomes and treatment resistance, indicating the high clinical risk of MEITL.
Conventional therapies for patients with T-cell prolymphocytic leukemia (T-PLL), such as cytotoxic chemotherapy and alemtuzumab, have limited efficacy and considerable toxicity. Several novel agent classes have demonstrated preclinical activity in T-PLL, including inhibitors of the JAK/STAT and T-cell receptor pathways, as well as histone deacetylase (HDAC) inhibitors. Recently, the BCL-2 inhibitor venetoclax also showed some clinical activity in T-PLL.
View Article and Find Full Text PDFArticle Synopsis
- The study examines the outcomes for patients with double or triple hit lymphoma (DHL and THL) treated with conventional R-CHOP chemotherapy versus more intensive chemotherapy.* -
- Among 160 patients followed for a median of 32 months, those receiving intensive chemotherapy had better progression-free survival (PFS) rates compared to those on R-CHOP, particularly in advanced stages, although overall survival (OS) showed no significant difference.* -
- The study highlights that elevated International Prognostic Index (IPI) scores and central nervous system (CNS) involvement are linked to worse survival outcomes, supporting the need for more prospective trials to establish treatment guidelines.*
A fifty-one years-old patient with a history of rheumatoid arthritis of recent diagnosis is hospitalized for exploration of a rapidly progressive anasarca state. First analysis discovered an impure nephrotic syndrome (acute renal failure, hematuria) and massive glomerular proteinuria. Auto-medication by nonsteroidal anti-inflammatory drug was revealed.
View Article and Find Full Text PDFDiagnosis criteria have been revised in 2014 and allow the treatment of some asymptomatic patients. Since 2015, a new prognostic score includes tumor plasma cells chromosomal abnormalities. It helps in the distinction between "standard risk" and "high risk" myelomas.
View Article and Find Full Text PDF